Will pursue joint development and commercialization of investigational RNAi therapy zilebesiran currently in Phase 2 trials for the treatment of hypertension.
To leverage Jnana’s RAPID chemoproteomics platform to discover small molecules for challenging-to-drug targets in cancer, immune and neurologic diseases.
An accelerated assessment by the EMA’s CHMP reviewed results from four studies of Actemra/RoActemra in over 5,500 patients with severe or critical COVID-19.
Newly launched medicines Tecentriq, Hemlibra, Ocrevus, Perjeta and Kadcyla offset the impact of competition from biosimilars for established medicines.
For the treatment of solid tumors expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion and ROS1-positive, advanced non-small cell lung cancer.
COVACTA trial did not meet primary endpoint of improved clinical status in patients with COVID-19 associated pneumonia, or the key secondary endpoints.